Rheumatoid Arthritis Flashcards

(41 cards)

1
Q

What is rheumatoid arthritis?

A

Chronic autoimmune disease characterised by pain, stiffness and symmetrical synovitis (inflammation of the synovial membrane) of synovial (diarthrodial) joints

Chronic = >6 weeks.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the key features of chronic arthritis?

A
  • Polyarthritis - swelling of the small joints of the hand and wrists is common
  • Symmetrical
  • Early morning stiffness in and around joints – takes a long time to start moving the joints. Indication that treatment works if this improves.
  • May lead to joint damage and destruction - ‘joint erosions’ on radiographs
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What extra-articular disease can occur in rheumatoid arthritis and what is this associated with?

A

Extra-articular disease = not just joint features.

Relates to IMMUNE COMPLEXES

  • Rheuamtoid nodules
  • Other rare: vasculitis, episcleritis.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Which antibody is detected in blood in rheumatoid arthritis?

A

Rheumatoid factor = IgM autoantibody against IgG

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Why is most commonly affected by rheumatoid arthritis?

A

1% of all population but 3:1 F:M ratio.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are the genetic and envrionmental risk factors for rheumatoid arthritis?

A

Genetic:

  • Disease concordance rates for twins: 15-30%(monozygotic) and 5%(dizygotic), heritability estimates up to 60%.
  • HLA-DRB gene variants; mapping to AAs 70-74 of DRbeta
  • Many DRB molecules are associated with RA but what they all have in common is a “shared epitope” in a peptide binding group - a specific amino-acid sequence which is strongly associated with RA

Environmental component:

Smoking - contributes 25% of population attributable risk and interacts with shared epitope to increase risk.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What are the most commonly affected joints in rheumatoid arthritis?

A
  • •Metacarpophalangeal joints (MCP)
  • •Proximal interphalangeal joints (PIP)
  • •Wrists
  • •Knees
  • •Ankles
  • •Metatarsophalangeal joints (MTP)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Name two types of deformities associated with joint damage and destruction i rheumatoid arthritis.

A
  • Swan-neck deformity
  • Boutonniere deformity
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Describe the swan-neck deformity.

A

Swan-neck deformity – there is hyper-extension at the PIP joint and hyper-flexion at the DIP joint

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Describe the Boutonniere deformity.

A

Boutonnière (‘button-like’) deformity – there is hyper-flexion at the PIP joint

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is the primary site of pathology in rhematoid arthritis? Give some examples of pathology.

A

Synovium: this includes the synovial joints, tenosynovium surrounding tendons, bursa.

Pathology examples:

  • proximal IP synovitis,
  • extesor tenosynovitis (swelling is between joints, on top of extensors, prevents extension of some fingers as some tendons may become damaged)
  • Olecranon bursitis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Describe the sub-cutaneous nodules that occur in rheumatoid arthritis. What percentage of patients get them? What is the typical place for such nodules?

A
  • Central area of fibrinoid necrosis surrounded by histiocytes and peripheral layer of connective tissue
  • Occur in ~30% of patients
  • Associated with:
    • Severe disease
    • Extra-articular manifestations
    • Rheumatoid factor
  • Usually occur in ulnar border of the forearm but the hands are also common (e.g. at PIP joints)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is rheumatoid factor also known as?

A

IgM anti-IgG antibody

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Which portion of the IgG antibody is targeted by rheumatoid factor?

A

Fc portion is recognised by the rheumatoid factor (IgM - which is pentameric)

This forms a large complex which is through to be the reason why nodules form.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What percentage of rheumatoid arthritis patients are rheumatoid factor positive? How many develop ot later?

A

Positive in 70% at disease onset and further 10-15% become positive over the first 2 years of diagnosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Name an antibody which is highly specific for rheumatoid arthritis.

A

Antibodies to citrullinated protein antigens (ACPA)

  • Antibodies to citrullinated peptides are highly specific for rheumatoid arthritis
  • AKA anti-cyclic citrullinated peptide antibody ‘anti-CCP antibody’
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What enzymes are responsible for the citrullination of peptides?

A

•Peptidyl arginine deiminases (PADs) —>

Arginine –> Citrulline

18
Q

Why do antibodies to citrullinated protein antigens (ACPA) form in rheumatoid arthritis?

A
  1. Caused by inflammatory cells? Inflammed synovium = high presence of neurophils and monocytes (which contain high concentrations of PADs) –> increased citrullination of autologous peptides i
  2. Smoking causes citrullination which causes the production of antibodies which are more pathogenic in the presence of a shared epitope–> increases ACPA-positive rheumatoid arthritis risk?
  3. Changes in microbiota?
  4. Chronic infections e.g. gingivitis due to poor dental health.
19
Q

What is the rheumatoid arthritis shared epitope?

A

Shared epitope= amino acids 70-74 of the HLA-DRb-chains associated with rheumatoid arthritis

20
Q

How could a shared epitope increase presence of ACPA?

A

ACPA is strongly associated with (smoking and) HLA ‘shared epitope’

  • Shared epitope preferentially binds non-polar aa’s like citrulline/citrulline containing peprtide antigens
  • but not positively charged aa’s like arginine
  • Citrulline is increased during inflammation
  • so ACPA more likely to develop among individuals with citrulinated autoantigens who have the shared eptiope
21
Q

Why was rheumatoid arthritis found to be associated with multiple HLA serotypes?

A

Because multiple HLA serotypes - HLA-DR4, -DR1, -DR6, DR10- contained the SHARED EPITOPE

Individuals with HLA-DR4 are not affected if they do not have the shared epitope which preferentially binds non-polar aa’s like citrulline.

22
Q

Name some common and uncommon extra-articular features of rheumatoid arthritis.

A

Common

  • Fever (due to cytokines), weight loss
  • Subcutaneous nodules

Uncommon

  • vasculitis
  • Ocular inflammation e.g. episcleritis
  • Neuropathies
  • Amyloidosis
  • Lung disease – nodules, fibrosis, pleuritis
  • Felty’s syndrome – triad of splenomegaly, leukopenia and rheumatoid arthritis
23
Q

What are the early, later and latest radiographic abnromalities seen in rheumatoid arthritis?

A

Early

  • Juxta-articular osteopenia

Later

  • Joint erosions at margins of the joint

Later still

  • Joint deformity and destruction
24
Q

Where in the synovium is the first place of bone erosion in rheumatoid arthritis?

A

Erosions occur initially at the margins of the joint where the synovium is in direct contact with bone (the ‘bare’ area)

25
Describe the composition of the synovium.
1-3 cell deep lining contains macrophage-like phagocytotic cells (type A synoviocyte) and fibroblast-like cells that produce hyaluronic acid (type B synoviocyte) type I collagen
26
What is the composition of synovial fluid?
Hyaluronic acid-rich viscous fluid
27
What is the composition of the articular cartilage in synovial joints?
* Type II collagen * Protteoglycan (aggrecan)
28
Describe the pathogenesis of rheumatoid arthritis.
Synovium becomes a proliferated mass of tissue (pannus) due to: * neovascularisation * lymphangiogenesis * inflammatory cells : * activated B and T cells * plasma cells * mast cells * activated macrophages * recruitement, activation and effector functions of these cells are controlled by cytokine network - excess of pro-inflammatroy vs anti-inflammatory cytokines.
29
What is the dominant pro-inflammatory cytokine in rheumatoid synovium? How do we know that it is detrimental in rheumatoid arthritis?
TNF-alpha Its actions are detrimental in this setting because TNFa inhibition is a therapeutic success in this condition. - done through parenteral administration of antibodies or fusion proteins.
30
In addition to cytokine blockade, what other treatment is available for rheumatoid arthritis?
B cell depletion by parenteral administration of antibody against CD20 (which is a B cell surface antigen) Drug: rituximab
31
What is the treatment goal for RA? What does this require?
_Preventing joint damage_ * **Multidisiplinary approach** - physiotherapy, occupational therapy, hydrotherapy, surgery * **DMARDs** - disease-modifying antii-rheumatic drugs * **Glucocorticoid** therapy e.g. steroids or prednisolone (short term to avoid side effects, but helps control flare of disease or inflammation of single joint) * **Biological therapies** can be potent and targeted
32
What are DMARDs?
disease modifying anti-rheumatic drugs - drugs that may induce REMISSION (not cure) and prevent joint damage.
33
What DMARDs are available for the treatment of rheumatoid arthritis?
* **Methotrexate** * **Sulphasalazine** * **Hydroxychloroquine** * Leflunomide (uncommon) * **Janus Kinase inhibitors:** Tofacitinib, Baricitinib * Gold and penicillamine (rarely used now)
34
Why are DMARDs started early in RA and why are they preferred over steroids?
* These are started early in the disease because **joint destruction = inflammation x time** * DMARDs offer **safer and more effective long-term treatment** than ‘steroids’ * So DMARDs are often referred to as **‘steroid-sparing agents’** * They enable us to avoid long-term steroid or at least use much lower doses of steroids than would be possible in their absence
35
How do DMARDs induce remission and prevent joint damage?
* Reduce the amount of inflammation in synovium * Slow or prevent structural joint damage e.g. erosions Complex mechanism of action and relatively slow onset of action i.e. weeks
36
What recaution must be taken with DMARD therapy?
Regular blood test monitoring as they have many side effects
37
Give examples of biological therapies available for RA?
**‘Anti-TNF' -** antibodies (infliximab, and others); fusion proteins (etanercept). **B cell depletion** - _Rituximab_ – antibody against the B cell antigen, CD20 **Modulation of T cell co-stimulation** - _Abatacept_ **Inhibition of interleukin-6** - _Tocilizumab_ (RoActemra) and _Sarilumab_ (Kevzara) – antibodies against IL-6 receptor. _NB: most biological therapies involve antibodies._
38
What is Abatacept and how does it work?
* Abatacept is a **fusion protein** - biological therapy for RA * Interferes with antigen presentation of T cells (**modulation of T cell co-stimulation)** * Extracellular domain of CTLA-4\* linked to modified Fc (hinge, CH2, and CH3 domains) of IgG1 \*cytotoxic T-lymphocyte-associated antigen 4
39
What are the side effects of biological therapies for RA? Give specific examples.
**Increased infection risk** Expensive so must follow guidance when using them _TNF-a inhibition_ - increased susceptibility to **mycobacterial infection e.g. tuberculosis** so need to screen all patients for TB before and use prophylactic antibiotics in those at high risk _B cell depletion_ - risk of **hepatitis B reactivation** so need to screen all patients for hepatitis B before treatment. It can be associated with **JC virus infection** and **progressive multifocal leukoencephalopathy (PML)** - rare
40
What are the risks associated with using B cell depletion therapy?
Associated with: * Hepatitis B reactivation (so need to screen all patients for hepatitis B before treatment) * JC virus infection * Progressive multifocal leukoencephalopathy (PML) - rare
41
What 2 drugs are used for the inhibition of IL-6?
1. Tocilizumab 2. Sarilumab (both antibodies against the IL-6 receptor)